Hims and Hers Stock: Share Price, Earnings & News 

Hims and Hers Health has become one of the most talked-about names in modern healthcare and stock markets. Founded to simplify access to medical care, the company has transformed how people approach wellness through digital platforms. 

Its rise reflects a shift in consumer behavior where convenience and privacy drive healthcare decisions. Hims and Hers connects patients directly to licensed professionals, offering treatments for issues once considered uncomfortable to discuss.

Overview of Hims and Hers Health

Hims and Hers Health Inc, known by its ticker symbol HIMS, is a modern telehealth company that focuses on personalized care. Founded in 2017 by Andrew Dudum, the company has redefined how people access healthcare. Its business operates primarily online, helping patients consult with licensed healthcare professionals through its platform. The company’s headquarters is based in San Francisco, California, and it serves millions of customers across the United States.

Hims and Hers started by offering treatments for common but sensitive health issues such as hair loss, erectile dysfunction, and acne. Over the years, it expanded into women’s health, mental wellness, dermatology, and weight management. 

The company’s goal is to remove stigma from healthcare and make treatment affordable and accessible to everyone through technology and subscription models.

Hims and Hers Website and Services

The company operates mainly through its websites, forhims.com and forhers.com. Both platforms are user-friendly and designed for quick online consultations. Users answer medical questionnaires, after which licensed professionals review their cases and prescribe treatment if appropriate. Medicines are then delivered discreetly to customers’ homes.

Services include sexual health, mental health therapy, skin and hair care, and weight-loss programs. The company has also introduced prescription medications for anxiety, depression, and sleep disorders. Hims and Hers has recently gained attention for offering weight-loss medications, including GLP-1 treatments, which are in high demand. This digital-first model has allowed Hims and Hers to grow rapidly in a competitive healthcare market.

Hims and Hers Stock Overview

Hims and Hers Health trades on the New York Stock Exchange (NYSE) under the ticker HIMS. As of October 2025, the Hims and Hers share price is around USD 56 per share. The company’s market capitalization is approximately USD 11 billion, showing how strongly investors view its growth potential. The stock has experienced significant price swings over the past few years, reflecting the changing outlook in the telehealth sector.

The company went public through a SPAC merger in early 2021. At that time, shares were priced near USD 10, but volatility quickly followed. The stock saw both rapid gains and deep corrections as investors tried to assess the long-term sustainability of the business model. In 2023 and 2024, shares rebounded as Hims and Hers demonstrated steady revenue growth and improved profitability.

Valuation and Investor Sentiment

Many analysts view Hims and Hers as an innovative but risky stock. Its valuation is considered high, mainly because of strong growth expectations. The price-to-earnings (P/E) ratio remains elevated compared to traditional healthcare companies. Investors are betting on the firm’s ability to sustain user growth and manage costs efficiently. The company does not pay dividends, focusing instead on reinvestment in research, marketing, and technology development.

Business Model and Revenue Streams

Direct-to-Consumer Approach

Hims and Hers operates through a direct-to-consumer (DTC) business model. This means it connects patients directly with licensed medical professionals, bypassing traditional healthcare intermediaries. Customers purchase subscription plans or single-use services through the company’s platform. This digital structure keeps overhead costs low and provides flexibility for customers seeking privacy and convenience.

Subscription and Product Sales

Most of the company’s revenue comes from monthly subscriptions. Users pay recurring fees for medications and telehealth consultations. Other sources include one-time product sales of over-the-counter supplements and skincare items. Hims and Hers also earns through partnerships with pharmacies and wholesale distribution of wellness products.

Expansion into New Areas

The company is expanding its product portfolio. In recent years, it entered the weight-loss market, offering GLP-1 medications and compounded alternatives. It also plans to grow into lab testing, diagnostics, and longevity-focused healthcare services. International growth has started through the acquisition of ZAVA, a European digital health company that operates in the UK and Germany.

Financial Performance and Earnings

Recent Quarterly Results

For the second quarter of 2025, Hims and Hers reported revenue of USD 544.8 million, representing an impressive 73% increase compared to the same period last year. The company now serves over 2.4 million active subscribers, reflecting steady user growth across its service categories. Gross margins remained strong at approximately 76%, highlighting efficient cost control and pricing power.

Full-year 2025 guidance suggests revenue between USD 2.3 and 2.4 billion, with adjusted EBITDA in the range of USD 60 to 70 million for the next quarter. This strong financial performance shows the company’s ability to scale operations while maintaining profitability. However, analysts remain cautious because of high marketing expenses and rising competition in the telehealth space.

Profitability and Cost Management

While Hims and Hers has achieved strong revenue growth, profitability is still under development. The company reinvests heavily in marketing and customer acquisition, which affects short-term profits. Despite this, its subscription model creates stable and predictable income. Over time, as customer loyalty increases and marketing costs decline, Hims and Hers could become a consistently profitable telehealth company.

Weight Loss Segment and GLP-1 Controversy

Weight management has become one of Hims and Hers’ fastest-growing divisions. The company introduced GLP-1 treatments, a class of drugs used for weight control and diabetes management. These medications gained massive popularity in the United States. Hims offered both branded and compounded versions to make them more affordable.

However, this approach led to complications. In 2025, Novo Nordisk, the maker of the branded drug Wegovy, ended its partnership with Hims and Hers. Novo claimed that the company violated certain terms related to selling compounded versions of GLP-1 drugs. Following this announcement, Hims and Hers’ stock fell by over 30% in a single trading session.

The incident drew attention from regulators and investors. Compounded medications are not FDA-approved in the same way as branded drugs, which means stricter oversight could affect sales. 

Despite this, Hims and Hers still expects around USD 725 million in annual revenue from its weight-loss division in 2025. The company aims to maintain customer trust through transparency and regulatory compliance.

Challenges and Risks

Regulatory and Legal Risks

Hims and Hers operates in a heavily regulated environment. Online prescriptions, telehealth consultations, and compounded medications all fall under strict federal and state rules. Any change in FDA or state regulations can directly affect operations. The weight-loss drug segment faces additional scrutiny, as regulators are reviewing compounded GLP-1 products more closely.

Market Competition

The telehealth market is becoming more crowded. Competitors like Teladoc Health, Ro, and Nurx offer similar digital services. Larger pharmaceutical companies are also investing in online healthcare, which increases pressure on pricing and innovation. To stay ahead, Hims and Hers must continue improving technology, user experience, and brand loyalty.

Dependence on Marketing

Much of the company’s growth relies on aggressive marketing and social media campaigns. While this strategy has brought millions of customers, it also adds significant costs. If customer acquisition becomes too expensive or conversion rates decline, profitability could be affected.

Recent News and Developments

Hims and Hers has been active in both expansion and restructuring. In early 2025, the company announced the closure of Apostrophe, its personalized dermatology brand, to focus on higher-growth segments like weight management and mental health. Around the same time, it launched a plan to expand into lab testing and longevity services.

The acquisition of ZAVA Health strengthened its presence in Europe, allowing it to operate in the UK, Germany, and France. The company also issued convertible senior notes worth USD 870 million to fund technology upgrades and international growth. Despite some recent setbacks, these steps show a clear vision for long-term diversification.

Conclusion

Hims and Hers stock represents both opportunity and caution. For investors seeking exposure to the growing telehealth market, it offers strong potential. Yet, it also carries risks tied to regulation and execution. As the company continues evolving, its performance in 2026 and beyond will determine whether its bold healthcare vision translates into sustained shareholder value.